Online Inquiry
CDKN1A (-/-) Cell Line
SPL-00915
Size | Price |
1 Unit | Online Inquiry |
Description |
---|
CDKN1A (-/-) |
Target Information | |
---|---|
Target Name | p21 Waf1/Cip1 |
Gene Abbr. | CDKN1A |
Gene ID | 1026 |
Full Name | cyclin dependent kinase inhibitor 1A |
Alias | CAP20, CDKN1, CIP1, MDA-6, P21 |
Species | Human |
Genomic Locus | 6p21.2 |
Introduction | This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-cyclin-dependent kinase2 or -cyclin-dependent kinase4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen, a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of cyclin-dependent kinase2, and may be instrumental in the execution of apoptosis following caspase activation. Mice that lack this gene have the ability to regenerate damaged or missing tissue. Multiple alternatively spliced variants have been found for this gene. [provided by RefSeq, Sep 2015]. |
Product Details | |
---|---|
Cell Line Model | HCT116 |
Genotype | CDKN1A (-/-) |
Description | CDKN1A (-/-) |
Parental ATCC ID | CCL-247 |
STR Profile | Amelogenin: X,Y; CSF1PO: 7,10; D13S317: 10,12; D16S539: 11,13; D5S818: 10,11; D7S820: 11,12; THO1: 8,9; TPOX: 8,9; vWA: 17,22; ATCC |
Disease | Colorectal carcinoma |
Tissue | Colon |
Gender | Male |
Key Endogenous Mutations | CDKN2A, CTNNB1, KRAS, PIK3CA, MLH1 |
CVT Selection Condition | G418 resistant - 0.3 mg/mL |
Cell Number | 1x10^6 |
Handling Specifications | |
---|---|
Revival | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 70-80% confluency, approximately 1:10-1:20. |
Culture Medium | RPMI 1640 including 2 mM L-glutamine and 25 mM sodium bicarbonate, supplemented with 10% FBS. |
Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 70-80% confluency, approximately 1:10-1:20. |
Freeze Medium | Complete growth media 45% + USDA approved FBS 50% + DMSO 5% |
Biosafety Level | BSL-1 |
Disclaimer | This product is classified under IATA regulations as a GMMO (genetically modified micro-organism) and will ship as UN3245. If applicable, ensure facility meets all requirements per local and country regulations. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.